Free Content Resistin gene 3′-untranslated region +62G→A polymorphism is associated with hypertension but not diabetes mellitus type 2 in a German population

Authors: GOUNI-BERTHOLD, I.1; GIANNAKIDOU, E.1; FAUST, M.1; KRATZSCH, J.2; BERTHOLD, H. K.3; KRONE, W.1

Source: Journal of Internal Medicine, Volume 258, Number 6, December 2005 , pp. 518-526(9)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

.  Gouni-Berthold I, Giannakidou E, Faust M, Kratzsch J, Berthold HK, Krone W (University of Cologne and Center of Molecular Medicine Cologne, Cologne; University of Leipzig, Leipzig; and Drug Commission of the German Medical Association, Berlin, Berlin; Germany). Resistin gene 3′-untranslated region +62G→A polymorphism is associated with hypertension but not diabetes mellitus type 2 in a German population. J Intern Med 2005; doi:10.1111/j.1365-2796.2005.01566.x Objectives. 

Resistin, a peptide hormone produced by adipocytes, has been associated with diabetes mellitus type 2 (DM-2) in some rodent models. In humans the exact function of resistin remains unknown. Some, but not all studies have found associations between polymorphisms in the resistin gene with DM-2. Recently a 3′-untranslated region +62G→A polymorphism of the resistin gene has been associated with decreased risk for DM-2 and for hypertension in diabetics in a Chinese population. Purpose of the present study was to examine for the first time in a German Caucasian population the possible association between this polymorphism and DM-2, hypertension, lipoprotein levels, resistin levels as well as atherosclerosis. Design, setting and subjects.

A total of 818 subjects participated in the study. The presence of the +62G→A polymorphism of the resistin gene was investigated using polymerase chain reaction-restriction fragment length polymorphism in 384 subjects with DM-2 [224 men, 160 women, age 63.4 ± 10.6 years, body mass index (BMI) 28.7 ± 5.1 kg m−2] and in 434 nondiabetic age- and sex-matched control subjects (248 men, 186 women, age 64.4 ± 6.5 years, BMI 26.5 ± 3.7 kg m−2). Results. 

Thirty-four subjects were found to be carrying the +62G→A polymorphism in the control and 24 in the diabetic group (allelic frequencies 4% and 3.2% respectively). Subjects with DM-2 were not found to have a different frequency of the genotypes (93.75% and 6.258%, for GG:GA/AA respectively) than the control subjects (92.2% and 7.8% for GG:GA/AA respectively) (OR 0.75, 95% CI 0.44–1.3, P = 0.31). In the total cohort, carriers of the A allele had a higher prevalence of hypertension (OR 1.82, 95% CI 1.03–3.21, P = 0.039). When analysed separately, the control group showed a strong association between the presence of the A allele and hypertension (OR 2.92, 95% CI 1.38–6.15, P = 0.005), whilst no such association could be established in the diabetic group (OR 1.05, 95% CI 0.43–2.54, P = 0.92). Multiple regression analysis confirmed that the presence of the A variant is associated with hypertension in control but not in diabetic subjects, independent of age and BMI. The polymorphism had no significant influence on the presence of atherosclerotic disease, BMI, and on triglyceride, HDL and LDL cholesterol levels, both, in the control and the diabetic groups. There was no difference in the serum resistin levels between the 62G→A variant carriers and noncarriers. Conclusions. 

In conclusion, the present data suggest that in a German Caucasian population the +62G→A polymorphism of the resistin gene is associated with hypertension but not with DM-2.

Keywords: +62G→A polymorphism; diabetes mellitus type 2; genotyping; hypertension; resistin

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2796.2005.01566.x

Affiliations: 1: Department of Internal Medicine II, University of Cologne and Center of Molecular Medicine Cologne (CMMC), Cologne 2: Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig 3: Drug Commission of the German Medical Association, Berlin; Germany

Publication date: 2005-12-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page